肢端肥大症患者的神经退行性疾病风险:一项队列研究
基于韩国国民健康保险系统2006至2016年数据,纳入1,611例肢端肥大症患者与8,055名年龄性别匹配对照,平均随访7.34年。肢端肥大症与帕金森病、全因痴呆、阿尔茨海默病及非阿尔茨海默病痴呆风险升高相关。
要点
- 肢端肥大症患者帕金森病风险高于对照(HR=2.609,95%CI:1.410-2.609)。
- 诊断治疗后前3年,肢端肥大症与全因痴呆(HR=2.299)、阿尔茨海默病(HR=2.228)及非阿尔茨海默病痴呆(HR=6.553)风险升高相关。
- 亚组分析中,合并糖尿病的肢端肥大症患者全因痴呆风险更高(交互作用P=0.028)。
核心结论
- 研究结果提示肢端肥大症与神经退行性疾病相关。
- 需进一步研究胰岛素样生长因子-1(IGF-1)/生长激素水平与神经退行性疾病之间的关联。
研究设计与样本
- 基于韩国国民健康保险系统数据库2006至2016年的队列研究。
- 纳入1,611例肢端肥大症患者和8,055名年龄、性别匹配的无肢端肥大症诊断对照,平均随访7.34年。
- 采用Cox比例风险回归分析,校正年龄、性别、家庭收入、地区、2型糖尿病、高血压和血脂异常。
主要发现
- 肢端肥大症患者与对照的平均年龄为54.16岁(男性占40.4%)。
- 肢端肥大症患者帕金森病发病率为1.54/1,000人年,显著高于对照组的0.55/1,000人年(log-rank检验p=0.001)。
- 肢端肥大症患者帕金森病风险高于对照(HR=2.609,95%CI:1.410-2.609)。
- 诊断和治疗后前3年内,肢端肥大症与全因痴呆(HR=2.299,95%CI:1.362-3.881)、阿尔茨海默病(HR=2.228,95%CI:1.191-4.168)和非阿尔茨海默病痴呆(HR=6.553,95%CI:1.754-24.482)风险升高相关。
- 亚组分析中,合并糖尿病的肢端肥大症患者较对照全因痴呆风险更高(交互作用P=0.028)。
局限性
- 需进一步研究IGF-1/生长激素水平与神经退行性疾病之间的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: A few recent studies have reported an association between insulin-like growth factor-1 (IGF-1) and neurodegenerative disease, but there was no report on any association between acromegaly and neurodegenerative disease. We investigated whether the risk of Alzheimer disease (AD), Parkinson disease, and other neurodegenerative diseases was increased among patients with acromegaly using nationwide data of Korea. METHODS: We studied the association between acromegaly and Parkinson disease and dementia in 1,611 patients with acromegaly and controls (age-matched and sex-matched 8,055 participants with no diagnosis of acromegaly) from the National Health Insurance System database between 2006 and 2016 with a mean follow-up period of 7.34 years. Cox proportional hazards regression analysis was used to assess the risk of all outcomes in patients with acromegaly compared with controls with adjusting for age, sex, household income, place, type 2 diabetes, hypertension, and dyslipidemia. RESULTS: The average age of the patients with acromegaly and the controls was 54.16 years (40.4% men). The incidence rate of Parkinson disease in patients with acromegaly (1.54 per 1,000 person-years) was significantly higher than that in the control group (0.55 per 1,000 person-years) (log-rank test p = 0.001). Acromegaly was associated with a higher risk of Parkinson disease (hazard ratio [HR] = 2.609, 95% CI: 1.410-2.609) than the control. In addition, acromegaly was associated with a higher risk of all-cause dementia (HR = 2.299, 95% CI: 1.362-3.881), Alzheimer disease (HR = 2.228, 95% CI: 1.191-4.168), and non-AD dementia (HR = 6.553, 95% CI: 1.754-24.482) than the control during the first 3 years after diagnosis and treatment. In subgroup analysis, diabetes was associated with higher risk of all-cause dementia (P for interaction = 0.028) in patients with acromegaly compared with controls. DISCUSSION: Our study results suggest that acromegaly is associated with neurodegenerative disease. Further study is needed on the association between IGF-1/growth hormone level and neurodegenerative disease.
引用
- Hong S, Han K, Kim KS, et al. Risk of Neurodegenerative Diseases in Patients With Acromegaly: A Cohort Study. Neurology. 2022. PMID: 36192177. doi:10.1212/WNL.0000000000201010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。